This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Apr 11, 2026
•
24 min read
Why the biotech of the future might be a lot smaller and a lot more nimble
Apr 10, 2026
8 min read
🧬 Eli Lilly launches obesity pill Foundayo at $149 - intensifying GLP-1 competition with Novo Nordisk's Wegovy, Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months, Avalyn Pharma plans IPO - developing inhalable IPF treatments for lung disease, Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention, Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155 + $50M investment
Apr 9, 2026
🧬 Jeito Capital raises $1.2B fund - investing in European clinical-stage drugmakers, Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing - $482M potential value, Gilead Sciences pauses M&A after acquiring Arcellx + Ouro Medicines + and Tubulis within six weeks
Apr 8, 2026
7 min read
🧬 Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal, E2 raises $80M Series C for next-gen thrombectomy treatment commercialization, Vertex Pharmaceuticals + Halozyme partner on Hypercon drug delivery technology - $15M upfront plus milestones
Apr 7, 2026
🧬 Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition - gaining rare obesity disorder drug Vykat XR, Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs, Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment
Apr 6, 2026
9 min read
🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones
Apr 2, 2026
🧬 Eli Lilly's Foundayo (orforglipron) wins FDA approval for obesity treatment following Ph3 success, Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding, Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform
Apr 1, 2026
🧬 Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market - ultimately challenging Takeda, Ambrosia Biosciences raises $100M Series B - developing oral weight-loss medications, BMS + Faro partner on multi-year AI clinical trial protocol improvement agreement
Mar 31, 2026
🧬 Blackstone closes $6.3B fund for life sciences investing and partnerships, Royalty Pharma's $500M investment to Johnson & Johnson to co-fund autoimmune antibody JNJ-4804, FDA approves Biogen's high-dose Spinraza ASO targeting SMN2 for SMA
Mar 30, 2026
🧬 Eli Lilly + Insilico Medicine expand AI drug discovery collaboration - $115M upfront + $2.75B total value, AstraZeneca's tozorakimab hits Ph3 endpoints for chronic obstructive pulmonary disease targeting IL-33 pathway, Terrestrial Bio raises $50M Series C - developing microarray patch therapeutic delivery platform
Mar 27, 2026
🧬 Pinnacle Medicines raises $89M Series B - advancing oral peptide therapeutics platform, Neion Bio emerges from stealth with egg-based biosimilar partnership to develop three monoclonal antibodies, Insilico Medicine + Tenacia Biotechnology expand AI-driven CNS collaboration with $94.75M deal value
Mar 26, 2026
🧬 Merck & Co. to acquire Terns Pharmaceuticals for $6.7B - targeting TERN-701 leukemia drug ahead of Keytruda cliff, Biogen + Alteogen partner on subcutaneous delivery tech - $20M upfront + $559M potential milestones, Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) wins FDA accelerated approval for Hunter syndrome neurologic manifestations
